Metabolomics Signature Can Predict Transition From Gestational Diabetes to Type 2 Diabetes
Metabolomics signature predicted the transition from gestational diabetes to type 2 diabetes.
(HealthDay News) — A metabolomics signature can predict the transition from gestational diabetes to type 2 diabetes, according to a study published in Diabetes.
Amina Allalou, from the University of Toronto, and colleagues enrolled a prospective cohort of 1035 women with gestational diabetes pregnancy at 6 to 9 weeks postpartum and screened them for 2 years for type 2 diabetes.
The researchers found that 113 of the 1010 women without type 2 diabetes at baseline progressed to type 2 diabetes within 2 years, and another 17 developed type 2 diabetes between 2 and 4 years.
Metabolomics were conducted with baseline fasting plasma in a nested case-control study involving 122 incident type 2 diabetes cases matched to non-cases by age, pre-pregnancy BMI, and race/ethnicity. Twenty-one metabolites that differed significantly by incident type 2 diabetes status were identified. Machine learning optimization was able to predict type 2 diabetes incidence with a discriminative power of 83.0% and 76.9% in the training set and an independent testing set, respectively.
"Our metabolomics signature predicted type 2 diabetes incidence from a single fasting sample," the researchers wrote. "This study represents the first metabolomics study of the transition from gestational diabetes to type 2 diabetes validated in an independent testing set, facilitating early intervention."